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Abstract

THE

REQUIREMENT

FOR VIABLE
in the

COAGULATION
of
HEPARINIZED

BLOOD

by
Karen L. Hay

PLATELETS

Activated coagulation times (ACT's) of heparinized blood or plasma
samples containing normal platelets were compared with ACT’s of heparin
ized samples containing non-viable or abnormally functional platelets.
The non-viable platelets were prepared by freeze/thawing, and the
abnormally functional platelets resulted from the addition of adenosine
or adenosine 5^diphosphate (ADP) .
The ACT’s of the heparinized samples containing treated platelets
were considerably longer than the ACT’s performed on samples with
untreated platelets.
samples, however.

Treated platelets had no effect on unheparinized
This would indicate that, although platelet factor 3

(PF3) is sufficient to promote clotting of unheparinized blood, viable
platelets, in addition, are required for clotting of heparinized blood.
A possible hypothesis which explains these findings is as follows:

In the unheparinized situation, coagulation factors
are activated as clotting takes place.

PF3 serves as a

surface catalyst, thrombin is generated, and a fibrin clot
is formed.

The form in which PF3 is available is incidental

to clot formation.
When heparin is present, however, thrombin is neutralized
as fast as it is formed.
fibrin formation

Quantities sufficient to induce

cannot therefore form in the free plasma,

and prolonged or infinite clotting times result.

In order

for coagulation to go to completion, an environment favorable
to thrombin generation must be provided.
It is probable that, even in heparinized samples, the
foreign surface present and the thrombin formed are
sufficient to promote platelet aggregation, even though the
ii

thrombin levels are too low to directly affect the coagulation
system.
The interstices of the platelet aggregates provide an
environment favorable to thrombin formation.

As the

platelets aggregate, plasma containing activated clotting
factors and heparin is trapped within the platelet clump.
Platelet factor 4 (PF4) is released from the platelets and.
in the static environment within the clump, is able to
completely neutralize the heparin trapped there.

This

then allows thrombin generation to proceed catalytically.
Fibrin formation can now go to completion, both within the
platelet aggregate and in the "plasmatic atmosphere"
closely surrounding the clump.

The large amounts of

thrombin generated overcome the heparin effect, and visible
clotting occurs.

The implications of an hypothesis such as this may be summarized
as follows:
1.

Viable platelets are essential to the coagulation of
heparinized blood and plasma samples.

2.

The varying sensitivities of different individuals to
comparable heparin doses may in part reflect the
platelet function of those individuals.

3.

The fact that variable (and sometimes considerable)
numbers of platelets remain in plasma used for activated
partial thromboplastin time (APTT) testing implies that
the APTT results on such heparinized samples will be
correspondingly variable.
iii

4.

The APTT, because it is not dependent on the patient's
own platelet level, cannot truly reflect that patient's
response to heparin.

5.

A test such as the activated coagulation time (ACT), which
is dependent on the patient's quantitative and qualitative
platelet level, reflects more accurately the actual
in vivo function of heparin than does the APTT.
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INTRODUCTION

Platelets have long been known to be intimately and actively
involved in blood coagulation.

The several platelet activities

associated with coagulation have been designated as platelet factors
1 to 4.
Platelet factor 1 (PF1) is not a native platelet protein in the
sense that it is merely adsorbed plasma coagulation factor V. (1)
Platelet factor 2 (PF2) is a true platelet protein, not adsorbed
from the plasma.

One of its main functions is the acceleration of

the thrombin-catalyzed conversion of fibrinogen to fibrin, possibly by
rendering fibrinogen a more sensitive substrate for thrombin.

Other

PF2 functions include its inhibitory effects on antithrombin-III, its
aggregating effects on platelets from platelet rich plasma (PRP), and
its potentiation of the platelet aggregating effect of ADP.

(2)

Aggregation of platelets does not, however, promote the release of
PF2 or enhance its action. (3)
Platelet factor 3 (PF3) activity can be attributed to the phospholipid portions of a lipoprotein component of the platelet membrane. (4)
The main phospholipids involved are phosphatidyl serine and phosphatidyl
ethanolamine.

(5)

PF3 is released when platelets undergo the aggregation

and release reactions and when platelets are exposed to trauma.

(6,7)

Rapid freezing and thawing have been used to release PF3 for assays of
platelet function. (8)

PF3 accelerates plasma clotting, probably by

acting as a surface catalyst for the coagulation factors.

(7)

It is

interesting to note that there is evidence indicating that plasma
factors are generally present in excess, and platelet concentration may
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3
be the limiting factor in determining the amount of thrombin formed
during blood clotting. (9,10)
Platelet factor 4 (PF4), also known as anti-heparin, is another
true platelet protein, a glycoprotein, localized mainly in the intracellular granule fraction. (11)

It is released during normal clotting

and following platelet aggregation by ADP, thrombin, epinephrine or
collagen.

(12-15)

It may also be released by rapid freezing and

thawing of platelets.

(16)

When released by the platelets, PF4 is in
When

the form of a high molecular weight proteoglycan-PF4 complex.

this complex comes into contact with heparin, the carrier portion of
the complex is displaced and the heparin binds to the PF4.

Heparin,

then, is essentially neutralized since no other glycosaminoglycan
present in vascular tissue will displace it from the PF4-heparin
complex.

(ID

Heparin is a highly acidic mucopolysaccharide whose precise
configuration is still unclear. (17)

It is present in minute amounts

in the normal blood, where its physiologic function is also unclear. (18)
However, it has been used extensively as a therapeutic anticoagulant
agent since its discovery in 1916 by Maclean. (17)
Although heparin interferes with several steps in the coagulation
mechanism, one of its primary functions is its neutralization of thrombin.
This action is due to its ability to enhance the effects of antithrombinIII on thrombin.

Several different theories of heparin-antithrombin III-

thrombin interaction have been offered to date, but the exact mechanism
of action remains

uncertain.

(17,19,20)

Heparin therapy has long been monitored using the whole blood
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clotting time (WBCT).

In recent years, however, the activated partial

thromboplastin time (APTT) has been increasingly used in preference to
the WBCT.

(21)

When it is necessary to neutralize heparin in vivo, protamine
sulfate is often administered.

(22)

Protamine sulfate, a strongly

basic low molecular weight protein. (17) combines with the strongly
acidic heparin to form a stable salt with the loss of anticoagulant
activity.

(23)

It may also be used to measure, by titration, the

concentration of heparin in in vitro blood samples.

(22)

OBJECTIVES

It is apparent that PF3 must be present in adequate concentration
in order for blood coagulation to proceed normally.

At first glance.

it would seem sufficient merely to have the necessary phospholipids
present, though perhaps not necessarily in the form of viable platelets.
This, in essence, is what is relied on when partial thromboplastin time
tests (activated or unactivated) are performed.

An artificial source

of phospholipid is used, making the test relatively independent of the
patient’s own platelet level.
It is possible, however, that in certain circumstances viable
platelets, capable of going through their aggregation and release
reactions, are necessary in addition to PF3 in order to promote normal
clotting,

An instance where this could be the case is the clotting

of heparinized blood .
The present study was done to demonstrate that, although PF3 alone
may be sufficient to promote normal blood coagulation in the absence of
heparin, the presence of viable, functional platelets is needed to
maximize clotting of heparinized samples.
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METHODS

AND

MATERIALS

Outline of Approach
The general approach to the problem was to compare the effects of
functional and abnormally or non-functional platelets on the clotting
times of heparinized whole blood or plasma samples.

Two main methods

were used:

1.

Effect of non-viable vs. normal viable platelets on the
ACT of heparinized plasma:
Samples of heparinized plasma were divided equally.
portion contained normal, untreated platelets.

One

The

platelets in the remainder were ruptured and rendered
non-viable by rapid freeze/thawing.

ACT's were then

performed on both samples.
2.

Effect of non-functional or abnormally functional vs.
normal viable platelets on the ACT of heparinized whole
blood:
Samples of heparinized blood were divided into three
equal portions.
platelets.

The first contained normal, untreated

The second was treated with adenosine to

inhibit platelet function.

The third was treated with

ADP to bring about platelet aggregation.
then performed on all three samples.

6

ACT's were

7
General methods
All blood was obtained from normal donors either by clean
venipuncture using 20-gauge needles and plastic syringes or through
the integral blood bank donor tubing.
Specimens were promptly divided into aliquots in plastic tubes
and treated with sodium heparin (1000 U/ml, beef lung, Upjohn Co •

9

Kalamazoo, Mi.) or placed in Vacutainer tubes containing EDTA (#3204,
Beckton, Dickinson & Co., Division of Bioquest, Rutherford, N.J.).
Baseline ACT's were performed on unheparinized samples using ACT
Vacutainer tubes (#3206X1534, Beckton, Dickinson & Co., Division of
Bioquest, Rutherford, N.J.) and a Type 5900 Dri-Bath (Thermolyne
Corp., Dubuque, Iowa) adjusted to 37°C.

Use of this type of heating

block, which has plexiglas windows on the sides, made it possible to
observe for clot formation without removing the tubes from the heatblock.
Whole blood samples were tested using 2 ml blood per ACT tube.

When

plasma samples were tested, the quantity of activator in the ACT tube
was altered, if necessary, to maintain approximately the same ratio of
plasma to activator as would have been present in a whole blood sample.
Complete details of the procedure used are listed in Appendix 2.
All other tests involving clot detection were performed using the
Fibrometer Precision Coagulation Timer, Model 5 (Baltimore Biological
Laboratories, Division of Bioquest, Cockeysville, Maryland).
include the protamine sulfate titration and the APTT.
procedures are given in Appendices 1 and 3.

They

Details of these

Specimens and reagents were

added using Oxford Samplers (Oxford Laboratories, Foster City, Ca.) of
appropriate volume.
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Hematocrit determinations were made using the Coulter Counter, Model
S (Coulter Electronics, Hialeah, Fla,).
Platelet counts were performed on the Thrombocounter (Coulter
Electronics, Hialeah, Fla,).
Platelet aggregating ability was measured using the Payton
Aggregometer, single channel (Payton Associates Inc • f Buffalo, New
York).

Specific Methods
Initial work on the project involved performing ACTfs on a series
of heparinized plasma pairs, one of which contained normal, viable
platelets, and the other which contained non-viable freeze/thawed
platelets.

It was postulated that the rapid freeze/thawing of the

one set of platelets would render these non-viable, but would still
permit them to contribute maximal amounts of PF3 to the clotting process.
Freeze/thawing has in fact been used as a method of releasing PF3 for
(8)
assay purposes and tests of platelet function. K '

It was also assumed

that the freeze/thawing process would release most of the platelets1
PF4 content, which in turn would affect the level of active heparin
present in the plasma samples under test.

So, upon completion of the

clotting process, protamine sulfate titrations were performed on all
sera and plasmas to determine the level of heparin remaining.
method used was a modification of that used by Bowie et al.

(24)

The
Since

the protamine sulfate titration is based on a thrombin time method,
test samples must contain fibrinogen (Factor I).

Because many of the

samples tested were sera, prothrombin-free beef plasma was used to supply
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Factor I.

Details of the protamine sulfate titration procedure are

given in Appendix 1.
The complete procedure, from venous collection and platelet
freeze/thawing to graph construction, is as follows:

1.

Collect venous blood by clean venipuncture and divide into
aliquots as follows:
Aliquots #1-3

Heparinize known quantities of
blood with precise amounts of
heparin, using plastic tubes.
(heparin concentrations used
ranged from 1.3 to 5.0

U/ml

whole blood or 2.2 to 8.2 U/ml
plasma)
Aliquot #4

Place 3-5 ml whole blood into a
Vacutainer tube containing EDTA
for hematocrit and platelet
determinations.

2.

Centrifuge aliquots #1-3 for 10 minutes @ 1000 rpm to obtain
platelet rich plasma (PRP).

While this is taking place,

perform hematocrit and platelet determinations on aliquot #4.
3.

Remove PRP's to a second set of labelled tubes.

4.

Recentrifuge remaining blood in original tubes for an additional
20 minutes @ 2500 rpm to obtain additional plasma,
this

to the PRP’s previously obtained.

and add

(Resultant PRP’s have

slightly lower platelet counts than initial PRP's, but sufficient
plasma is thus made available for further testing.)
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5.

Divide PRP’s into two equal portions and treat each as follows:
Portion //I

leave untreated

Portion #2

Centrifuge for 20 minutes @
2500 rpm to obtain platelet poor
plasma (PPP) and a platelet button.
Carefully remove supernatant PPP
to a second set of labelled tubes,
taking care not to disturb the
platelet button.

6.

Perform platelet counts on both PRP’s and PPP's.

(Preferably,

PPP's should have counts of less than 15xl03/cu mm, and ideally
less than 10xl03/cu mm.)
7.

Freeze/thaw the platelet buttons 6 to 8 times using an ice bath
(dry ice in methanol) and a 37°C waterbath.

8.

Return

the PPP’s to their corresponding freeze/thawed platelet

buttons and resuspend.
9.

Perform ACT’s on all plasmas.

Use approximately the same

ratio of activator to plasma as would be present in a whole
blood ACT.

Activator from more than one ACT tube may be

combined to obtain the necessary ratio.

Carry timing out

to at least 20 minutes before declaring any samples unclottable.
10.

Calculate the heparin concentration initially present in each
plasma sample as follows:
units heparin added
ml whole blood

11.

x

100
plasmacrit

units heparin
ml plasma

Construct a curve relating plasma heparin concentration to
ACT times using linear graph paper.

Assign ACT times to the
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ordinate and heparin concentrations to the abscissa.
12.

Centrifuge all samples for 5 minutes @ 2500 rpm.

Remove the

supernatant plasma or serum samples to a new set of labelled
tubes.
13.

Perform protamine sulfate titrations on all samples to
determine the amount of heparin remaining in each.

14.
i

Construct a curve relating initial heparin to residual heparin
using linear graph paper.

Assign initial heparin to the

abscissa and residual heparin to the ordinate.

The second approach used for illustrating the need for viable
platelets in the coagulation of heparinized blood was based on the
effects of adenosine and ADP on platelets.

ADP is known for its ability

to induce platelet aggregation and release. (25)

Adenosine, on the other

hand, inhibits these functions. (26)
Heparinized blood was treated with adenosine (Sigma Chemical Co.,
St. Louis, Mo.) to render the platelets non-functional for comparison
with freeze/thawed platelets.

The final plasma concentrations of

adenosine varied from 6 to 95 mM.

Aggregometer studies indicated that

in adenosine concentrations of less than 20 mM, platelets were still
able to undergo at least partial aggregation before clotting occured.
Concentrations of adenosine greater than 40 mM, however, were able to
completely inhibit platelet aggregation, even in the presence of large
amounts of thrombin sufficient to induce coagulation.

The methods

employed in these Aggregometer studies are detailed in Appendix 4.
ADP (sodium salt, equine muscle)(Sigma Chemical Co., St. Louis, Mo.)
was added to heparinized blood to determine the effect of pre-clumped
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platelets on the clotting times of these samples.
used were in the range of 9 to 28 mM.

ADP concentrations

The ADP had been stored frozen

for some time, so its actual functional concentration may have been
lower.

These concentrations of ADP, however, were well able to

bring about platelet aggregation.
To rule out the possibility that the concentrations of ADP and
adenosine used had any significant direct effect on the coagulation
system, they were added to normal citrated plasma and APTT’s were
performed.

The APTT method which was used is given in Appendix 3.

Details of the ADP-adenosine approach to the need for viable
platelets are as follows:
1.

Collect venous blood by clean venipuncture and divide into
aliquots as follows:
Aliquot #1

Use 2 ml unheparinized blood for
a baseline ACT.

Aliquots #2-4

Heparinize known quantities of
blood with precise amounts of
heparin.

Use plastic tubes and

maintain at 37°C.
Aliquot #5

Place 3-5 ml whole blood into a
Vacutainer tube containing EDTA
for hematocrit and platelet
determinations.

2.

Perform the baseline ACT on aliquot #1.

3.

Divide each of aliquots #2-4 into three equal portions and
treat as follows:
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Portion #1

Add a precise amount of adenosine.
Mix and incubate at 37°C for 2 to
4 minutes.

Portion #2

Add a precise amount of ADP.

Mix

and incubate at 37°C for 2 to 4
minutes.
Portion #3

Leave untreated, but keep at 37°C
until ready for further testing.

4.

Perform ACT’s on all samples prepared in step #3.

Maintain

the same ratio of blood to activator as would be used when
performing a routine ACT.

Carry timing out to at least 20

minutes before declaring any samples unclottable.
5.

Construct a curve relating heparin concentration to ACT times
using linear graph paper.

Assign ACT times to the ordinate

and heparin concentrations to the abscissa.

(Heparin

concentrations may be expressed in either U/ml whole blood or
U/ml plasma, as the reaction pattern should be identical in
either case.

Since hematocrit values were not available for

two of the individuals tested, U/ml whole blood were used for
these.)
units heparin added
ml whole blood

x

100
plasmacrit

units heparin
ml plasma

RESULTS

Response to heparin levels
Different donors showed markedly differing responses to heparin.
Plasma samples from

as shown in Figure 1 (solid line) and Table 1.

donors 2 and 4 had very different ACT results although their heparin
and platelet levels were essentially equal.

Samples from donor 4

showed a much steeper slope, and hence a much greater sensitivity to
heparin, than did samples from donor 2.

Effect of activation or clotting on the heparin level of plasma
Figure 2 and Table 3 show the results of tests on six individuals.
Heparin levels in this series ranged from 2.2 to 8.2 U/ml plasma.
Eighty-five percent of the heparin added was still active and measurable.
using a modified protamine sulfate titration technique, following
activation or clotting of plasmas containing viable platelets.

An

average of seventy-four percent of the original heparin was recovered
following the activation or clotting of plasma samples containing
freeze/thawed platelets.

Effect of non-viable (freeze/thawed) platelets on the ACT of heparinized
PRP
Samples containing freeze/thawed platelets showed much longer ACT's
than did those containing viable platelets (Tables 1 & 2, Figure 1).
This effect was much more pronounced at higher heparin levels (Figure 1).
Although samples with viable platelets clotted at heparin levels ranging
as high as 7.2 U/ml, none of the samples with freeze/thawed platelets
clotted at heparin concentrations over 2.4 U/ml.
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Plasma samples which initially showed the steepest slopes on
incremental addition of heparin also showed the greatest prolongation
of the ACT when the platelets were rendered non-viable by freeze/thawing.
For example, samples from donor 2 (Figure 1) showed initial ACT results
of 6 minutes 30 seconds at a heparin concentration of 7,0 U/ml.

Samples

from donor 4 showed no sign of clot formation at this same heparin level.
and had a 17 minute clotting time at a heparin concentration of only
4.7 U/ml, indicating the much greater sensitivity of donor 4 to heparin
initially.

After the platelets were freeze/thawed, samples from donor

2 had a 4 minute clotting time at a 2.3

U/ml heparin concentration.

while samples from donor 4 showed no clot formation at any of the
heparin concentrations tested.

Effect of adenosine on the ACT of heparinized blood
The plasma adenosine concentrations used ranged from approximately
6 to 95 mM.

Increasing concentrations of adenosine progressively

prolonged the ACT of heparinized blood (Figure 3, dashed lines).
effect was most apparent at the higher heparin levels.

This

The adenosine

effect decreased with decreasing heparin level, and there was no effect
whatsoever in the absence of heparin, as indicated by equal ACT results
at zero heparin concentration in any one donor (Figures 3 & 4).

APTTfs

performed on normal, unheparinized plasma to which adenosine had been
added gave similar results.

There was no effect on coagulation of

unheparinized plasma at adenosine concentrations of 25 mM or less, and
only negligible effect at concentrations as high as 100 mM (Table 4).
Figure 4 gives the results of whole blood ACT’s performed on samples
from six donors.

As in the case of the freeze/thawed platelets.
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specimens initially most sensitive to heparin showed the greatest
prolongation of the ACT when treated with adenosine.

For instance.

samples from donor 9 were initially much more sensitive to heparin
than were samples from either donor 11 or 12 (solid lines).

Following

addition of adenosine, blood from donor 9, with a plasma adenosine
concentration of only 19.8 mM, showed no clotting at heparin levels as
low as 2 U/ml (dashed line), while blood from donors 11 and 12, each
with adenosine concentrations greater than 80 mM, clotted at heparin
levels exceeding 8 U/ml,

Effect of ADP on the ACT of heparinized blood
As was the case with adenosine, a dose-related response to ADP
was very evident (Figures 3 and 4).

ADP had its greatest effect on

highly heparinized samples, and had negligible effect on unheparinized
samples (Figure 4, Table 4).

DISCUSSION

It has long been known that PF4, an anti-heparin, is present in
the granule fraction of platelets and is released following platelet
aggregation and during blood coagulation.

It is probable that the

15% decrease in heparin level observed following the coagulation of
normal, heparinized PRP was due to the release of endogenous PF4
during the coagulation process.

The more complete release of PF4

brought about during the freeze/thawing process probably accounts for
the additional 11% lost' from samples containing freeze/thawed platelets.
Since the freeze/thawing process releases PF3, which accelerates
clotting, and PF4, which neutralizes heparin, it might be anticipated
that heparinized samples containing freeze/thawed platelets would clot
more readily than would samples containing viable platelets.
not the case.

This was

This observation supports the proposal that viable

platelets play a vital role in the coagulation of heparinized blood.
The results obtained using blood samples treated with adenosine
provide further support.

Platelets were rendered increasingly

incapable of aggregating under stimulus as the adenosine concentration
was raised.

And likewise, increasing adenosine concentrations

resulted in proportionately longer ACT’s of heparinized blood.
The possibility that the adenosine was directly affecting the
clotting system is unlikely since, at zero heparin concentration.
the presence of adenosine did not prolong the ACT.

The fact that

APTT’s of unheparinized plasmas were only mildly affected by high
adenosine concentrations further strengthens this argument.
Although viable platelets are required for clotting of heparinized
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blood, they are apparently not required for clotting of unheparinized
samples.

This is demonstrated by the fact that, for any one donor.

ACT results at zero heparin concentration were equal, whether or not
the platelets had been treated.
An hypothesis which could explain the need for viable platelets
in heparinized blood samples is as follows:
In unheparinized blood, coagulation factors are
activated as clott-ing takes place.

PF3 serves as a surface

catalyst, thrombin is generated, and a fibrin clot is formed.
The form in which PF3 is available is incidental to clot
formation.
When heparin is present, however, thrombin is neutralized
as fast as it is formed.

Quantities sufficient to induce

fibrin formation can therefore not form in the free plasma.
and prolonged or infinite clotting times result.

In order

for coagulation to go to completion, an environment favorable
to thrombin generation must be provided.
It is probable that, even in heparinized samples, the
siliceous earth activity and the thrombin formed are sufficient
to promote platelet aggregation, even though the thrombin
levels are too low to directly affect the coagulation system.
The interstices of the platelet aggregates provide an
environment favorable to thrombin formation.

As the platelets

aggregate, plasma containing activated clotting factors and
heparin is trapped within the platelet clump.

PF4 is released

from the platelets and, in the static environment within the
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clump, is able to completely neutralize the heparin trapped
there.

This then allows thrombin generation to proceed

catalytically.

Fibrin formation can now go to completion,

both within the platelet aggregate and in the plasmatic
atmosphere closely surrounding the clump.

The large amounts

of thrombin generated overcome the heparin effect, and
visible clotting occurs.

The addition of ADP to heparinized blood prior to activation
produced prolonged clotting times similar to those obtained with
adenosine.

This would seem to indicate that, in order for a favorable

environment to be provided, activated clotting factors must be incor
porated into the clump at the time it is formed.

It appears that,

if the aggregate is formed before activation is applied, the plasma
trapped within the clump is isolated and remains unactivated unless
activated clotting factors can diffuse in from the surrounding free
plasma.
This hypothesis has significant clinical implications.

It has

long been known that patients with low platelet counts are much more
sensitive to heparin than are patients with normal counts.

It has

been thought that this is due mainly to the resultant lower PF4 levels.
An even more important reason may be that, with low platelet counts.
a limited number of favorable environments for thrombin generation are
formed and the anticoagulant effect of heparin cannot be overcome.
Individuals vary in their response to heparin even when their
platelet counts are comparable.

Although this could well be attributed

to variations in coagulation factor concentration and activity, it may
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also be explained by the fact that malfunctioning platelets, such as
those produced experimentally with adenosine and ADP, cannot undergo
normal aggregation and release.

An environment favorable to thrombin

generation is not formed, and these individuals are more sensitive
to heparin.

The variation of response from individual to individual

may thus be a partial expression of the function of that individual^
platelets.
The implications of this hypothesis extend to the tests used in
monitoring heparin therapy.
for many years.

The WBCT has been the method of choice

The APTT, though, is being increasingly used today.

Unlike the WBCT, the APTT relies on an artificial source of PF3 and
has thus been thought to be independent of a patient’s own platelet
level.

However, since platelets apparently are essential to the

clotting of heparinized blood, the APTT cannot truly reflect a patient’s
response to heparin.
To make matters worse, the normal centrifugation procedures used
for preparing plasma samples do not render these samples truly platelet
free.

Samples which have been centrifuged for five minutes @ 2500 rpm

in preparation for APTT’s may have plasma platelet counts as high as
3
300 x 10 /cu mm.
Attempts to run an APTT on such a sample would
result in the performance of a test which more closely approximates
the ACT.

The variability introduced into APTT results is obvious.

For these reasons, the APTT is not the best method for monitoring
the response of patients to heparin therapy.

A test, such as the ACT,

which is dependent on the patient’s quantitative and qualitative plat
platelet level, gives a more accurate indication of the actual in vivo
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function of heparin in these patients.
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Donor
//

1

2

3

4

5

6

Table 1;

Initial
Platelet
Heparin
Count
(U/ral plasma) (xl03/cu ram)

ACT
(min, sec)

3.3

no clot @ 20’

4.9

no clot @ 20f

8.2

no clot @ 20’

2.3

536

2'30"

4.7

550

5* 00"

7.0

468

6f 30"

2.3

444

3* 30"

4.6

414

7 1 00"

6.9

457

2.3

547

5* 00"

4.7

599

17’00"

7.0

519

no clot @ 28f

2.4

160

4100"

4.8

169

6I40"

7.2

177

9’50"

2.2

172

5'00"

4.4

189

9’ 25"

6.5

119

no clot @ 23’

15-19

ACT’s of heparinized plasma samples
containing viable platelets, different
individuals showing differing degrees
of response to heparin.
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Donor
#

1

2

3

4

5

6

Table 2:

Initial
Initial
Viable pits
Remaining
Platelets
Heparin
(U/ml plasma^ (xl03/cu mm) (xl03/cu mm)

ACT
(min, sec)

3.3

no clot @ 20f

4.9

no clot @ 20f

8.2

no clot @ 20*

2.3

536

9

4f 00"

4.7

550

5

no clot @ 21*

7.0

468

5

no clot @ 21*

2.3

444

38

4.6

414

38

no clot @ 30 t

6.9

457

56

no clot @ 30'

2.3
4.7

547

74

no clot @ 28f

599

57

no clot @ 28*

7.0

519

72

no clot @ 28’

2.4

160

11

S’OO"

4.8

189

10

no clot @ 23*

7.2

177

8

no clot @ 23*

2.2

172

14

10*00"

4.4

189

13

no clot @ 23*

6.5

119

11

no clot @ 23*

11*00"

ACT*s of heparinized plasmas containing non-viable
(freeze/thawed) platelets.
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Donor
#

Initial
Heparin
(U/ml)
3.3

1

2

3

4

5

6

VIABLE PLATELETS
Residual
Residual
Heparin
Heparin
(U/ml)
(%)
85
2.8

4.9

4.2

86

3.7

76

8.2

7.7

94

7.4

90

2.3

1.6

68

1.6

68

4.7

5.5

118

2.5

53

7.0

6.8

97

4.5

64

2.3

1.8

79

1.4

61

4.6

3.2

70

3.6

79

6.9

5.6

82

4.0

58

2.3

1.5

64

0.6

26

4.7

4.0

86

3.3

71

7.0

6.2

88

5.8

83

2.4

1.8

75

1.6

67

4.8

4.4

92

4.4

92

7.2

7.2

100

6.6

92

2.2

1.3

60

1.9

88

4.4

3.2

74

3.6

83

6.5

6.9

106

7.2

110

Mean =85 %
S.D. = 15.1%
C.V. = 17.8%
Table 3:

NON-VIABLE PLATELETS
Residual
Residual
Heparin
Heparin
(U/ml)
(%)
70
2.3

Mean =74 %
S.D. = 18.7%
C.V. = 25.3%

Effects of viable and non-viable (freeze/thawed) platelets
on sample heparin levels following activation or clotting.
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Additive
None

APTT (secs)

INTERPRETATION

37

Adenosine:
100 mM

44

50 mM

43

25 mM

39

12.5 mM

37

Adenosine has no direct effect on
the coagulation system at concen
trations of 25 mM or less, and
negligible effect at concentra
tions of 50 mM and greater.

ADP:
11.7 mM

41

5.9 mM

36

3.0 mM

37

1.4 mM

35

ADP has no direct effect on the
coagulation system at concentra
tions of 5.9 mM or less, and
negligible effect at concentra
tions of 11.7 mM and greater.

(Platelets = 327xl03/cu mm plasma)
Table 4:

Effects of adenosine and ADP on the APTT of
normal unheparinized citrated plasma
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APPENDIX
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APPENDIX 1
Protamine Sulfate Titration
Reagents
Imidazole buffer, pH 7.4 (stock solution)
1.

Dissolve 1.36 gm imidazole powder (#14603, Eastman Organic
Chemicals, Rochester, N.Y.) in triple-distilled water and
make up to 100 ml in a volumetric flask.

2.

Add 13.6 ml 0.1N HC1 to 25 ml of this imidazole solution.

\

and dilute to 100 mL with triple-distilled water.
3.

Adjust to pH 7.4.

Store at 1-6°C.

Imidazole-buffered saline (working solution)
Add one volume of the stock imidazole buffer (pH 7.4) to two
volumes 0.85% NaCl.
Protamine sulfate, 10 mg/ml (stock solution)(Upjohn Co •» Kalamazoo, Mi.)
Reconstitute the contents of one 50 mg vial of protamine sulfate
with 5.0 ml bacteriostatic water in accompanying vial.
Protamine sulfate, 100 yg/ml (working stock solution)
Bring 1.0 ml stock protamine sulfate (10 mg/ml) to 100 ml with
Solution is stable for several months

imidazole-buffered saline.

at 1-6°C.
Protamine sulfate (working serial dilutions)
Tube No.
Imidazole buffered
saline (ml)
Protamine sulfate,
100 yg/ml (ml)
Mix and transfer
(ml)
Protamine sulfate
Con. (yg/ml)

CN CO ■vf

uo

oo

vO

<T\

m
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o
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o

00

m
LD

<r
vo

CO CM

CO On

o o o o o o o o o o

CN CO

o

o
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VO

r-'-

00

00 O'. vC m <r CO
o
o o o o o o o

CN CO

UO VO
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Oi
CM CM CM

in

o o o
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o

CM CM CM
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o
o o o
CM CM CM

o m o m o m o m o m o m o m o m o m o m m
.
n- vo vO m m
o CTv ov 00 00
CO CO CM CM
CM
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Thrombin, 100 units/ml (stock solution)
Reconstitute one bottle of Bovine Thrombin, Topical, 1000 units.
(Parke, Davis & Co • * Detroit, Mi.) with a mixture of 5 ml
imidazole-buffered saline and 5 ml glycerol.
stabilizes the thrombin.

The glycerol

Store at l-6°Co

Thrombin (working solution)
Dilute an aliquot of the stock thrombin solution with imidazolebuffered saline until it gives a clotting time of 20-25 seconds
when tested with the normal control plasma as
1.

shown below:

(24)

Add 0.1 ml normal control plasma to duplicate prewarmed
fibrocups.

2.

Add 0.1 ml imidazole-buffered saline.

3.

Warm 3 minutes.

4.

Place the fibrocups under the 0.3 ml probes of a fibrometer.

5.

Add 0ol ml prewarmed thrombin dilution.

6.

Record duplicate times to the nearest 10th of a second, and
determine average time.

START TIMER.

(Duplicates should agree within

one second.)
NOTE:

It is important that the thrombin dilution be mixed as

little as possible (no more than 3-4 inversions), and that it
be made in a plastic rather than glass tube or container.

If

these precautions are not taken, the thrombin dilution will
deteriorate at a very rapid rate.
Normal control plasma (Verify Normal Citrate, General Diagnostics,
Division of Warner-Lambert Co • > Morris Plains, N.J.)
Reconstitute with distilled water as directed on the vial label.
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Prothrombin-free beef plasma (Hyland, Division of Travenol Laboratories Inc • > Costa Mesa, Ca,)
Reconstitute with distilled water as directed on the vial label.

Procedure
The method used is a modification of that given by Bowie et al.

(24)

Since over half of the samples tested were sera, prothrombin-free beef
plasma was used to supply fibrinogen.

The procedure is performed as

follows:
1.

Prepare the reagents as listed above.

2.

Record the times obtained when calibrating the thrombin working
solution.

3.

Perform protamine sulfate titrations on the test samples as
follows:
3. •

Add 0.1 ml of desired protamine sulfate dilution to
duplicate prewarmed fibrocups.

b.

Add 0o05 ml prothrombin-free beef plasma.

c.

Add 0.05 ml test plasma or serum.

d.

Warm 3 minutes, then place fibrocups under the 0.3 ml
Fibrometer probes.

e.

Add 0.1 ml prewarmed thrombin working solution and
START TIMER.

f.

Record duplicate times to the nearest 0.1 second and
determine the average time.

Continue testing in this manner, using various protamine sulfate
concentrations, until a neutralization point for the heparin
level has been obtained.
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4.

Retest the normal control plasma (as in calibration of the
working thrombin solution) to verify that the thrombin has
retained its activity.

Normal control times should be within

3-4 seconds of the initial values for the thrombin working
solution to be considered stable.
5.

Plot the results of each titration on linear graph paper.
placing clotting times on the ordinate and protamine sulfate
concentrations on the abscissa.

6.

Determine from the graph the most dilute concentration of
protamine sulfate which is capable of completely neutralizing
the heparin present in the sample (i.e.

the lowest protamine

sulfate concentration capable of correcting the test time to
the normal control time).
7.

Convert the resultant protamine sulfate concentration into its
equivalent heparin concentration and multiply the results by
2 to obtain the heparin concentration in units/ml plasma or
serum.

NOTE:

Although 1.0 mg protamine sulfate is stated to neutralize

90 U.S.P, units of sodium heparin (beef lung), an exact
relationship was obtained for each batch of reagents by
heparinizing a plasma sample with a known amount of heparin, and
then assaying this sample for heparin content.

The resultant

relationship was then used in calculating all test results.’

APPENDIX 2
Activated Coagulation Times
Procedure
The method used is a modification of that given by Hattersley

(27,28)

and is performed as follows:

1.

Place specimen into a prewarmed ACT tube and immediately start
a stopwatch.

A ratio of 2 ml whole blood per ACT tube is

ideal and should be maintained.

When plasma samples are to

be tested, alter the quantity of activator in the ACT tube, if
necessary, to maintain approximately the same ratio of plasma
to activator as would have been present in a whole blood
sample.
2.

Mix well by rapid inversion and place into a 37°C heatblock.

3.

Starting at 30 seconds, tilt the heatblock and tubes through
a 45° angle in front of a bright light source at the following
intervals:
Clotting time < 5 minutes

5-second intervals

» O

Clotting time = 5-10 minutes

15-second intervals

Clotting time > 10 minutes

30-second intervals

Observe for beginning clot formation.

Clot detection is

facilitated if the tube is rotated while it is tilted so that
the blood runs down the sides of the tube.

Timing should

continue for at least 20 minutes before a sample is declared
unclottable.
NOTE:

Tilting should be done very gently, especially when

testing samples which have prolonged ACT times, as the clots
are very fragile and are easily broken by too vigorous tilting.
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APPENDIX 3
Activated Partial Thromboplastin Time

(29,30)

Reagents
Platelin Plus Activator (General Diagnostics, Division of WarnerLambert Co • 9 Morris Plains, N.J.)
Reconstitute with distilled water as directed on the vial label.
Calcium chloride, 0o02M (Dade Division American Hospital Supply
Corp • 9 Miami, Fla.)
Normal control plasma. (Verify Normal Citrate, General Diagnostics,
Division of Warner-Lambert Co • 9 Morris Plains, N.J,)
Reconstitute with distilled water as directed on the vial label.

Procedure
1,

Prepare the reagents as listed above.

2.

Pour approximately 1 ml CaCl2 into a clean test tube, and place
it in a 37°C heatblock to warm.

3.

Add 0,1 ml well-shaken Platelin Plus Activator to duplicate
fibrocups.

Let warm 3-4 minutes.
Start stopwatch.

4.

Add 0.1 ml plasma (control or test).

5.

Incubate 5 minutes at 37°C, mixing well at the beginning and
again at the end of the incubation period, then place under
the 0.3 ml Fibrometer probes.
START TIMER.

6.

Add 0.1 ml prewarmed CaCl2*

7.

Record duplicate times to the nearest 10th of a second, and
report average time to the nearest second.
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APPENDIX 4
Aggregometer Check of Adenosine Potency

Reagents
Thrombin, Topical, 1000 units (Parke, Davis & Co • * Detroit, Mi.)
Adenosine (Sigma Chemical Co • 9 St. Louis, Mo.)
Procedure
To determine the amount of adenosine sufficient to prevent clumping
of platelets, even in the presence of high concentrations of thrombin.
the following was performed, using a Payton Aggregometer.

1.

Calibrate the Aggregometer output to least transmittance with
PRP, and to greatest transmittance with PPP.

2.

Perform the following steps with different concentrations of
thrombin to determine the concentration of thrombin sufficient
to induce complete and irreversible platelet aggregation
without inducing coagulation (approximately 0.18 U/ml should be
sufficient).
a.

Place 0.5 ml PRP into a suitable cuvette, and insert
the cuvette into the Aggregometer slot.

b.

Add a magnetic stirrer and set mixing speed to 1100 rpm.
Wait 2-3 minutes until temperature and graph plot have
stabilized.

c.

Add 0o05 ml thrombin of known concentration and observe
the effect on the graph.

When the desirable thrombin concentration has been determined.
continue with the following steps.
3.

Place 0.5 ml fresh PRP in Aggregometer and wait until temperature
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and graph plot have stabilized.
4.

Add 0.05 ml adenosine of known concentration and observe the
effect on the graph.

Wait until the graph reading has

stabilized.
5.

Add 0.05 ml thrombin in a concentration sufficient to induce
aggregation but not coagulation, and observe the effect on the
graph.

If there is no change in the graph reading, continue

adding increasing amounts of thrombin until either the platelets
aggregate or the plasma clots.
r

Interpretation
If the platelets aggregate before the plasma clots, the adenosine
concentration is insufficient.

Steps 3-5 must then be repeated with

increasing concentrations of adenosine.
If the plasma clots before aggregation takes place, repeat steps
3—5 using lower concentrations of adenosine to determine if adenosine
is present in just adequate amounts or in large excess.
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